Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-10-05 am EDT
1329.00 GBX   +0.05%
09:13aETF Preview: ETFs, Futures Decline Pre-Bell After Private Payroll, Trade Deficit Reports
MT
05:15aGSK Says Non-Small Cell Lung Cancer Therapeutic Candidate Met Primary Endpoint in Phase 2 Study
MT
05:09aGSK's Lung Cancer Combination Therapy Shows Shrunken Tumors In Mid-stage Study
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ViiV Healthcare Announces Support for Community-Based Organizations With New Monkeypox Emergency Response Fund in the US

08/10/2022 | 04:24am EDT

DURHAM, N.C. - ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced an emergency response fund for community-based organizations that are responding to the monkeypox virus outbreak, which last week the US Department of Health and Human Services declared a public health emergency as the US outbreak has grown into the largest in the world.[i]

As monkeypox cases surge across the US and disproportionately affect LGBTQ communities, particularly men who have sex with men, and people living with HIV, ViiV Healthcare's Positive Action Monkeypox Emergency Response Fund will make available $500,000 in grants to help community-based organizations who serve people living with HIV respond to the emerging Monkeypox public health crisis.

Lynn Baxter, Head of ViiV Healthcare North America, said: "We see again the critical role that community-based organizations play in responding to public health emergencies and pandemics. Our Monkeypox Emergency Response Fund is designed to help frontline, grassroots organizations respond to the monkeypox emergency in the US by providing much needed financial support to continue their work and meet the urgent need for monkeypox prevention, screening and education. For the past 30 years, we have worked alongside community-based organizations to address the evolving needs of the HIV community and this fund is another example of our ongoing support."

ViiV Healthcare's Monkeypox Emergency Response Fund will support US community-based organizations. Eligible US organizations should submit applications via the online grants portal at https://viivhealthcare.fluxx.io/ for up to $50,000 to support increased outreach, education, testing, and access to prevention and care for monkeypox in community settings. Funding cannot be used for the provision of medical care or the salaries of licensed medical professionals. Applications may be submitted on a rolling basis between August 10 and September 30, 2022. For more information, see the Request for Proposals here.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined as a shareholder in October 2012. The company's aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com/company.

ViiV Healthcare enquiries:

Media enquiries:

Audrey Abernathy

+1 919 605 4521

(North Carolina)

GSK enquiries:

Media enquiries:

Kathleen Quinn

+1 202 603 5003

(Washington DC)

Tim Foley

+44 (0) 20 8047 5502

(London)

Dan Smith

+44 (0) 20 8047 5502

(London)

Analyst/Investor enquiries:

Nick Stone

+44 (0) 7717 618834

(London)

James Dodwell

+44 (0) 20 8047 2406

(London)

Mick Readey

+44 (0) 7990 339653

(London)

Josh Williams

+44 (0) 7385 415719

(London)

Jeff McLaughlin

+1 215 751 7002

(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:

GSK plc ViiV Healthcare Limited

No. 3888792 No. 06876960

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

[i] US Centers for Disease Control and Prevention.2022 Monkeypox Outbreak Global Map available at 2022 Monkeypox Outbreak Global Map | Monkeypox | Poxvirus | CDC. Accessed August 9, 2022.

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC 0.05% 1329 Delayed Quote.-19.18%
PFIZER, INC. -0.76% 44.12 Delayed Quote.-24.71%
All news about GSK PLC
09:13aETF Preview: ETFs, Futures Decline Pre-Bell After Private Payroll, Trade Def..
MT
05:15aGSK Says Non-Small Cell Lung Cancer Therapeutic Candidate Met Primary Endpoint in Phase..
MT
05:09aGSK's Lung Cancer Combination Therapy Shows Shrunken Tumors In Mid-stage Study
MT
02:12aGsk : announces positive headline results from PERLA, the phase II trial of Jemperli (dost..
PU
10/04Vir Biotech gets U.S. funding for flu-prevention antibody
RE
10/04GSK : JP Morgan sticks Neutral
MD
10/03GSK : Deutsche Bank reiterates its Neutral rating
MD
09/29Haleon Launches Exchange Offers for Seven Series of Notes
MT
09/29Central banks are here to save the day
MS
09/29Ooddo BHF Upgrades GSK to Outperform from Neutral, Lifts PT
MT
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 28 235 M 31 760 M 31 760 M
Net income 2022 4 409 M 4 960 M 4 960 M
Net Debt 2022 13 626 M 15 328 M 15 328 M
P/E ratio 2022 11,6x
Yield 2022 4,57%
Capitalization 53 802 M 60 521 M 60 521 M
EV / Sales 2022 2,39x
EV / Sales 2023 2,27x
Nbr of Employees 90 096
Free-Float 93,7%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 328,40 GBX
Average target price 1 835,51 GBX
Spread / Average Target 38,2%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-19.18%61 509
JOHNSON & JOHNSON-3.19%435 445
ELI LILLY AND COMPANY16.41%313 453
ROCHE HOLDING AG-12.23%279 092
ABBVIE INC.4.87%251 052
PFIZER, INC.-24.71%249 525